Page last updated: 2024-08-25

buparvaquone and Toxoplasmosis, Congenital

buparvaquone has been researched along with Toxoplasmosis, Congenital in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aguado-Martínez, A; Barrett, LK; Choi, R; Ferre, I; Hemphill, A; Hulverson, MA; Maly, DJ; McCloskey, MC; Moreno-Gonzalo, J; Müller, J; Ojo, KK; Ortega-Mora, LM; Van Voorhis, W1

Other Studies

1 other study(ies) available for buparvaquone and Toxoplasmosis, Congenital

ArticleYear
Development of a murine vertical transmission model for Toxoplasma gondii oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis.
    The Journal of antimicrobial chemotherapy, 2017, 08-01, Volume: 72, Issue:8

    Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Female; Infectious Disease Transmission, Vertical; Male; Mice; Naphthalenes; Naphthoquinones; Piperidines; Pyrazoles; Toxoplasmosis, Animal; Toxoplasmosis, Congenital; Treatment Outcome

2017